Gunderson Dettmer represented client Interline Therapeutics, a data science and healthcare company, in its $92 million Series Seed and Series A financing led by Foresite and Arch Ventures.

In the announcement of the transaction, CEO of Interline Zachary Sweeney said, “The synergies between the technologies — from physics to biology to genetics — converged in the past five year to enable what we are doing. We think we are going to change the way drug discovery is done and change the foundation that will be expected for drug projects in the future.”

The Gunderson deal team was led by Tim Ehrlich and included Mark Foster, David Horne, Erik Thompson, Chris Crawford and Genevieve Crescenzo.